Drugs and Treatment - MOPH Qatar Diabetes Newsletter - 28th Feb 2018

    View this newsletter in full

Blood pressure drug helps prevent onset of diabetes: Study

A drug commonly used to control high blood pressure may also help prevent the onset of type 1 diabetes in up to 60 per cent of those at risk for the disease, a study has found. The drug, methyldopa, has been used for over 50 years to treat high blood pressure in pregnant women and children, according to the study published in the Journal of Clinical Investigation.
27th Feb 2018 - Deccan Chronicle

Blood pressure drug may help prevent type 1 diabetes: study

17th Feb 2018 - The Asian Age

Foot screening could identify heart irregularities

A specialised type of foot check aimed at diagnosing a heart problem could reduce the risk of people with diabetes experiencing stroke, a study has found. The Northern Diabetes Footcare Network is urging for the introduction of an annual foot pulse-test in the UK to diagnose Atrial Fibrillation (AF), which can cause irregular heart rate and lead to a greater risk of stroke if not treated. The call comes following the publication of the results of a three-month pilot foot pulse-test which suggested that the health service in the North East could benefit from a saving of £500,000. The cost of a stroke is £23,315 per person, which is what the calculations in the Podiatry and Atrial Fibrillation Case Finding are based on.
26th Feb 2018 - Diabetes.co.uk

Study examines safety, efficacy of ertugliflozin in type 2 diabetes

Canadian researchers conducted a Phase III randomized trial involving 461 adults with inadequately controlled type 2 diabetes and found that those who received ertugliflozin 5mg/day or 15mg/day experienced a -0.9% and a -1% mean change in glycated HbA1C from baseline to week 52, respectively, compared with the placebo group. The findings in Diabetes, Obesity and Metabolism revealed that the ertugliflozin group also had reductions in fasting plasma glucose, systolic blood pressure and body weight.
26th Feb 2018 - American Association of Nurse Practioners

Notts woman successfully undergoes pioneering diabetes treatment

A woman thought to be the first to have undergone a pioneering diabetes treatment at one of the city's hospitals says it has been a success. Sue King underwent a treatment involving a small balloon inserting water into the intestines, which is being trialled in the city. This helps to combat a yet-to-be-identified hormone, which is known to be present in the intestines, that causes issues for insulin created by the body. Those with diabetes currently rely on drugs to control their blood sugar level, but this treatment is designed to restore the body's ability to regulate its blood sugar level. As well as reducing that reliance, it is also hoped the treatment will reduce costs in the long run.
26th Feb 2018 - Nottingham Post

Diabetic kids learn how to inject themselves with “fun, intuitive” insulin kit

Discussed at this year’s Design Indaba, product designer Renata Souza has created a prototype colourful insulin pen and illustrated tattoo kit, which aims to teach children with type one diabetes how to inject themselves and reduce the stigma of the disease.
26th Feb 2018 - Design Week

Thomy toolkit could make life easier for children with type-1 diabetes

23rd Feb 2018 - Dezeen

Preventing a million diabetic foot amputations

People with diabetes who develop neuropathy don’t feel pain when they are injured, so they may not notice soft tissue damage in the foot (or elsewhere) until the damage is quite extensive. Many of these people also have peripheral artery disease (PAD) as a result of poor blood circulation to the legs. PAD reduces a person’s ability to fight infection and puts them at a higher risk of developing foot ulcers. People with diabetes have a 25% chance of getting foot ulcers. And if a person develops a foot ulcer they are at an increased risk of amputation because of infection and other related complications. Diabetes is one of the main causes of lower-limb amputation.
26th Feb 2018 - The Conversation UK

Roche's Sinking Diabetes Unit Looks Toward a Monster for a Boost

Roche Holding AG has enlisted a little green monster with a gap-toothed smile to help rescue its diabetes business after a decade of declining sales. The gremlin is the mascot of mySugr, an Austrian startup Roche bought for 70 million Swiss francs ($75 million) last June. The deal gave Roche’s struggling diabetes unit a chance to own a cutting-edge technology in at least one area of care: smartphone apps. The harmless character masks a menacing reality for Roche. As the number of people with diabetes swells to nearly half a billion, insurers are cutting prices of the blood-sugar monitoring equipment that patients rely on. Instead of selling its business, as some competitors have done, Roche is betting on a digital turnaround.
26th Feb 2018 - Bloomberg

New video and leaflets designed to help young diabetes patients in Worcestershire take control of their own health and treatment

Funded by the Bournville Charitable Trust, a video has been produced involving real patients which aims to allay some of the fears and answer some of the questions about moving from paediatric to adult diabetes services in Worcestershire. It is thought to be just the second initiative of its kind in the country. The film shows a young local diabetes patients discussing some of the issues which concern them about the management of their condition and them meeting two other patients, who have gone through the process themselves. The filming was done at Worcester Countryside Centre and Kidderminster Hospital and Treatment Centre. One of the patients who has moved onto adult services is 27-year-old University of Worcester student Chris Bright. He was diagnosed with type 1 diabetes aged eight but took the decision that he would not let the condition rule his life but made it fit around his lifestyle.
26th Feb 2018 - Worcester News

First medicine to treat neonatal diabetes

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for Amglidia (glibenclamide), a medicine indicated for the treatment of neonatal diabetes mellitus (NDM), for use in newborns, infants and children.
26th Feb 2018 - Wired-gov.net

"I just pray" – Tongan diabetes sufferers face death sentence as Kingdom won't fund costly dialysis centre

It's believed up to 15,000 Tongans have diabetes, but the Pacific nation is putting its resources into reducing critical levels of largely-preventable type-two diabetes and shying away from efforts in managing Type 1 diabetes
26th Feb 2018 - TVNZ 1

Diabetes monitor is "game changer"

A new method of measuring blood glucose levels in people with diabetes is a significant advance in the management of the disease, according to an independent assessment by University of Manchester, Manchester University NHS Foundation Trust and Derby Teaching Hospitals experts. The FreeStyle Libre flash glucose monitor has been available on prescription in the United Kingdom from November 2017. It works through a white disc adhered to the arm which connects remotely to a small monitoring device. It is designed to replace the recommended 4-10 painful finger-stick blood glucose tests required each day for the self-management of diabetes. The disc is replaced every 14 days and can also be purchased by people with diabetes.
22nd Feb 2018 - The University of Manchester

Glucose monitor now available on the NHS is diabetes "game changer"

23rd Feb 2018 - The Engineer

Liva Healthcare aims to bring human touch to digital diabetes management

A healthcare platform that connects patients with lifestyle and disease management coaches is being trialled by the NHS as a possible means of preventing and managing diabetes. Liva Healthcare is one of several solutions being piloted as part of the NHS ...
22nd Feb 2018 - Digital Health

Low statin use in people with diabetes despite cardioprotective effects

Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack, stroke and related death were not prescribed one, according to a research letter published in the Journal of the American College of Cardiology. The analysis also showed wide variation in statin use across cardiology practices included in the study. Previous studies have shown that taking a statin can significantly cut the risk of a future cardiovascular event in people with diabetes.
21st Feb 2018 - Knowridge